SPil

OPE [X] First Class Mail or [] Express Mail Certificate

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: COESTER, Carl-Fr

Group Art Unit: 1614

Serial No.

AUG' 1 5 2005

10/515,984

Examiner:

Filing or 371 (c) Date: 7/6/2005

Atty. Dkt. No: FZ002-US

For: PHARMACEUTICAL ACTIVES SUBSTANCE COMBINATION AND THE USE

THEREOF

Ťo:

Mail Stop Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Fm:

24222

CERTIFICATE OF MAILING 37 CFR 1.8: I certify that this correspondence is being deposited on the below date with the U.S. Postal Service with sufficient postage as FIRST CLASS MAIL addressed to: Mail Stop Amendment, Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

Date:

8/10/05

M Dawn M. Case

Commissioner:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is the Applicant's Information Disclosure Statement, <u>2</u> sheets form PTO/SB/08A and/or PTO/SB/08B, and <u>11</u> references and other information. Pursuant to 37 CFR 1.98 (a)(2)(i) applicant has not transmitted herewith copies of cited U.S. Patents and U.S. patent application publications as the above application was filed after June 30, 2003. Please enter in the above application and communicate in all related matters with the undersigned.

All necessary fees are intended to be included, however the Office is hereby authorized to charge any deficiency or credit any overpayment in the fees to deposit account #500323.

Respectfully submitted,

Vernon C. Maine, Reg. No. 37,389

Scott J. Asmus, Reg. No. 42,269

Andrew P. Cernota, Reg. No. 52,711

Attorneys/Agents for Applicant

Cus. No. 24222 Maine & Asmus PO Box 3445 Nashua, NH 0300

Nashua, NH 03061-3445

Tel. No. (603) 886-6100, Fax. No. (603) 886-4796

Info@maineandasmus.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

le Application of: COESTER, Carl-Fr

Group Art Unit: 1614

Serial No.

10/515,984

Examiner:

Filing or 371 (c) Date: 7/6/2005

Atty. Dkt. No: FZ002-US

For: PHARMACEUTICAL ACTIVES SUBSTANCE COMBINATION AND THE USE

THEREOF

To:

Mail Stop Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Fm: 24222

CERTIFICATE OF MAILING 37 CFR 1.8: I certify that this correspondence is being deposited on the below date with the U.S. Postal Service with sufficient postage as FIRST CLASS MAIL addressed to: Mail Stop Amendment, Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

Date:

8/10/05

N Dawn M. Case

Commissioner:

INFORMATION DISCLOSURE STATEMENT

Applicants submit this statement and the attached 2 sheet(s) of form PTO/SB/08A and/or PTO/SB/08B and 11 references and other information in accordance to the duty of disclosure under 37 C.F.R. §§1.56,1.97, and 1.98, and requests consideration hereof. Pursuant to 37 CFR 1.98 (a)(2)(i) applicant has not transmitted herewith copies of cited U.S. Patents and U.S. patent application publications as the above application was filed after June 30, 2003.

Compliance with 37 C.F.R. §1.97: This Information Disclosure Statement is filed within three (3) months of the filing date of a National Application or before the mailing date of a first office action on the merits. No fee or certification is required.

<u>Information Cited:</u> The Applicants hereby make of record in the above-identified application, the information listed on the attached form PTO/SB/08A and/or PTO/SB/08B. The order of presentation of the references should not be construed as an indication of the importance of the reference. As all the references listed on attached Form PTO/SB/08A and/or PTO/SB/08B are in English, no commentary is required.

<u>Remarks</u>: A copy of each reference, together with a listing on Form PTO/SB/08A and/or PTO/SB/08B, is submitted herewith. Applicants respectfully request that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

- 2. The enclosed form PTO/SB/08A and/or PTO/SB/08B be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application; and
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined in 37 C.F.R. §102.

Notwithstanding any statement by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

Vernon C. Maine, Reg. No. 37,389

Scott J. Asmus, Reg. No. 42,269

Andrew P. Cernota, Reg. No. 52,711

Attorneys/Agents for Applicant

Cus. No. 24222 Maine & Asmus PO Box 3445 Nashua, NH 03061-3445

Tel. No. (603) 886-6100, Fax. No. (603) 886-4796

Info@maineandasmus.com

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/RAS

บร-

Sheet 1

AUG 1 5 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete il Known			
Application Number	10/515,984		
Filing Date	07/06/2005		
First Named Inventor	Coester, Carl-Fr		
Art Unit	1614		
Examiner Name			
Attorney Docket Number	F7002-US		

		· · · · · · · · · · · · · · · · · · ·		DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		^{US-} 4,131,675	12-26-1978	Silverstrini	
		^{US-} 4,162,318	07-24-1979	Silverstrini	
		US-			
	<u> </u>	US-			
	<u> </u>	US-			
		US-			
	<u> </u>	US-			
	 	US-			
	†	US-			
	 	US-			
		US-			
	†	US-			
	<u> </u>	US-			,
	<u> </u>	US-	_		
		US-	1		
	ı		1	1	

Examiner Cite		FORE Foreign Patent Document	IGN PATENT DOCU Publication	Name of Patentee or	Pages, Columns, Lines,	Т
Initials*	No.¹	Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T⁵
		WO 99/13884 A1	03-25-1999	Sandyk, Reuven		
		WO 02/056892 A2	07-25-2002	The Brigham and Wom-		
		DE 2836149	03-15-1979	Silvestrini, Bruno		L
		DE 2720194	11-24-1977	Silvestrini, Bruno		
		DE 3443820 A1	06-20-1985	Bristol Myers Co.		

Examiner	Date	
Signature	Considered	
-		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitute for for A449/PTO	Application Number	10/515,984		
INFORMATION DISCLOSURE	Filing Date	07/06/2005		
STATEMENT BY APPLICANT	First Named Inventor	Coester, Carl-Fr		
(Use as many sheets as necessary)	Art Unit	1614		
(Use as many sneets as necessary)	Examiner Name			
Sheet 2 of 2	Attorney Docket Number	FZ002-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		DE Search Report dated March 27, 2003 of Patent Application No. DE 102 23 254.7 filed May 24, 2002.	
		DE Search Report dated July 9, 2003 of Patent Application No. DE 102 54 822.6 filed November 25, 2002.	
		GEROLDI, CRISTINA et al., "Drug Treatment in Lewy Body Dementia", Dement Geriatr Cogn Disord, 1997, pp. 188-197, Vol. 8, S. Karger AG, Basel.	
		IWONA ZEBROWSKA-LUPINA et al., "INTERACTION OF ANTIDEPRESSANTS WITH ANTIPARKINSONIAN AGENTS IN RATS", Pol. J. Pharmacol. Pharm, 1995, pp. 885-874, Vol. 37.	
		ROJAS-FERNANDEZ, CARLOS H. et al., "Dementia with Lewy Bodies: Review and Pharmacotherapeutic Implications", Pharmacotherapy, 1999, pp. 795-803, Vol. 19, No. 7.	
		TERI, L. et al., "Treatment of agitation in AD", Neurology, Nov. 2000, pp. 1271-1278, Vol. 55, AAN Enterprises Inc.	

		0.0.00
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.